ImmunityBio (NASDAQ:IBRX) Shares Gap Up – Time to Buy?

ImmunityBio, Inc. (NASDAQ:IBRX)’s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $2.82, but opened at $2.99. ImmunityBio shares last traded at $2.9730, with a volume of 12,266,023 shares traded.

ImmunityBio News Summary

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Company reports preliminary net product revenue of ~$113M for 2025 (a ~700% YoY increase), a major inflection in commercial sales that underpins today’s rally. ImmunityBio Reports Continued Execution and Sales Momentum
• Positive Sentiment: Media coverage highlights the 700% revenue surge and frames it as a catalyst for renewed investor interest and momentum. ImmunityBio (IBRX) Stock Surges 30% on 700% Revenue Growth
• Positive Sentiment: Updated QUILT‑106 CAR‑NK data: durable complete responses up to ~15 months in Waldenström lymphoma, which supports pipeline value beyond Anktiva. ImmunityBio Announces Durable Complete Response of 15 Months
• Positive Sentiment: QUILT‑2.005 (first‑line BCG‑naïve NMIBC) enrollment >85% and company now anticipates full enrollment by Q2 2026 with a potential BLA submission by year‑end — accelerates regulatory pathway for a label expansion. ImmunityBio Advances First-Line BCG Naive NMIBC Program
• Positive Sentiment: Anktiva received accelerated approval in Saudi Arabia and continued international approvals/expansions are cited as drivers of the global sales ramp. Accelerated Saudi approval for ImmunityBio’s Anktiva
• Positive Sentiment: H.C. Wainwright and other analysts/publications are affirming buy stances and positive outlooks on Anktiva/label expansion potential, adding credibility to the story. H.C Wainwright Asserts Buy Stance
• Neutral Sentiment: ImmunityBio presented at the J.P. Morgan Healthcare Conference — useful for incremental detail and management commentary but not a single clear stock catalyst. ImmunityBio Presents at J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Hedge‑fund and institutional interest (coverage noting Citadel, etc.) is increasing — signals positioning but not a direct operational change. ImmunityBio’s 700% Revenue Boom Becomes Citadel’s Latest I-Told-You-So
• Negative Sentiment: Some coverage warns the rally is extended and suggests profit‑taking; investors should weigh fast appreciation, remaining net losses and execution risk before buying. ImmunityBio Extends Gains to 10th Day — Time to Book Profits?

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on IBRX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of ImmunityBio in a report on Monday, December 29th. Jefferies Financial Group upped their target price on shares of ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Finally, D. Boral Capital reissued a “buy” rating and issued a $24.00 price target on shares of ImmunityBio in a research report on Tuesday. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $11.50.

ImmunityBio Stock Performance

The company’s 50-day moving average is $2.22 and its 200-day moving average is $2.42. The firm has a market cap of $5.44 billion, a price-to-earnings ratio of -13.46 and a beta of 0.03.

ImmunityBio (NASDAQ:IBRX) last announced its earnings results on Wednesday, November 5th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. The company had revenue of $32.06 million during the quarter, compared to the consensus estimate of $31.88 million. On average, analysts predict that ImmunityBio, Inc. will post -0.92 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Armistice Capital LLC acquired a new stake in shares of ImmunityBio in the 2nd quarter valued at $20,497,000. Heights Capital Management Inc. acquired a new stake in ImmunityBio in the third quarter worth about $16,152,000. Vanguard Group Inc. increased its position in ImmunityBio by 26.8% in the third quarter. Vanguard Group Inc. now owns 27,655,205 shares of the company’s stock worth $68,032,000 after purchasing an additional 5,837,898 shares during the period. AlphaCore Capital LLC bought a new stake in ImmunityBio during the 2nd quarter worth about $7,854,000. Finally, Woodline Partners LP lifted its position in ImmunityBio by 53.7% during the 3rd quarter. Woodline Partners LP now owns 5,297,725 shares of the company’s stock valued at $13,032,000 after purchasing an additional 1,851,854 shares during the period. 8.58% of the stock is currently owned by institutional investors.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.